ATE325865T1 - Isolierung von sezernierte proteine exprimierenden zellen - Google Patents

Isolierung von sezernierte proteine exprimierenden zellen

Info

Publication number
ATE325865T1
ATE325865T1 AT02713420T AT02713420T ATE325865T1 AT E325865 T1 ATE325865 T1 AT E325865T1 AT 02713420 T AT02713420 T AT 02713420T AT 02713420 T AT02713420 T AT 02713420T AT E325865 T1 ATE325865 T1 AT E325865T1
Authority
AT
Austria
Prior art keywords
poi
isolation
cells expressing
secreted proteins
cell
Prior art date
Application number
AT02713420T
Other languages
English (en)
Inventor
James P Fandl
Neil Stahl
Gang Chen
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE325865T1 publication Critical patent/ATE325865T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02713420T 2001-01-16 2002-01-16 Isolierung von sezernierte proteine exprimierenden zellen ATE325865T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26199901P 2001-01-16 2001-01-16

Publications (1)

Publication Number Publication Date
ATE325865T1 true ATE325865T1 (de) 2006-06-15

Family

ID=22995765

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713420T ATE325865T1 (de) 2001-01-16 2002-01-16 Isolierung von sezernierte proteine exprimierenden zellen

Country Status (9)

Country Link
US (3) US6919183B2 (de)
EP (1) EP1392859B1 (de)
JP (1) JP4323167B2 (de)
AT (1) ATE325865T1 (de)
AU (1) AU2002245272B2 (de)
CA (1) CA2434802C (de)
DE (1) DE60211329T2 (de)
IL (2) IL156910A0 (de)
WO (1) WO2002057423A2 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325865T1 (de) * 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
GB0118337D0 (en) * 2001-07-27 2001-09-19 Lonza Biologics Plc Method for selecting antibody expressing cells
CN1668634A (zh) * 2002-05-22 2005-09-14 比奥根艾迪克Ma公司 分泌性多肽的检测
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7771969B2 (en) 2003-08-20 2010-08-10 Celltech R&D Limited Methods for obtaining antibodies
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
AU2007248559A1 (en) 2006-05-04 2007-11-15 Abmaxis Inc. Cross-species and multi-species display systems
BRPI0712073B8 (pt) 2006-05-17 2021-05-25 Hoffmann La Roche ácido nucléico para produção de um polipeptídio ou proteína heteróloga
DK2102239T3 (da) * 2006-11-30 2012-05-29 Res Dev Foundation Forbedrede immunoglobulin-biblioteker
JP5675109B2 (ja) * 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
EP2617827A1 (de) 2007-03-26 2013-07-24 Celexion, LLC Zelloberflächenanzeige, Abtastung und Herstellung von Proteinen von Interesse
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
WO2009103753A1 (en) * 2008-02-20 2009-08-27 Ablynx Nv Methods for identifying and/or sorting cells by secreted molecule and kits for performing such methods
CA2715212A1 (en) 2008-03-03 2009-09-11 Glycofi, Inc. Surface display of recombinant proteins in lower eukaryotes
US8067339B2 (en) * 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
EP2918606B1 (de) * 2008-12-04 2018-07-11 Korea Research Institute of Bioscience and Biotechnology Screening von abundant sezernierten Proteinen und deren Verwendung als Fusionspartner zur Herstellung rekombinanter Proteine
DK2808393T3 (en) 2009-06-02 2018-03-12 Regeneron Pharma Cells insufficient for fucosylation
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8278873B2 (en) * 2009-09-10 2012-10-02 Syntheon, Llc Surgical sterilizer with integrated battery charging device
KR20120117931A (ko) * 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
EP2390661B1 (de) * 2010-05-02 2015-06-24 Miltenyi Biotec GmbH Verankerungs-/Erfassungsmittel zum Auswählen oder Analysieren einer CHO-Zelle entsprechend einem Produkt, das von der CHO-Zelle sezerniert wird
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US8986956B2 (en) 2010-11-04 2015-03-24 Korea Research Institute Of Bioscience And Biotechnology Method for producing human epidermal growth factor in large volume from yeast
IL210093A0 (en) * 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
US20140038842A1 (en) 2010-12-28 2014-02-06 Xoma Technology Cell surface display using pdz domains
EP3252076B1 (de) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostische verwendung von antikörpern gegen das protein ror-1
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
CN102680679B (zh) * 2011-03-15 2014-08-27 中国科学院上海生命科学研究院 检测单细胞特异性抗体分泌的细胞微孔芯片及其制备方法
SG11201401716XA (en) 2011-10-28 2014-05-29 Novartis Ag Novel purine derivatives and their use in the treatment of disease
CN104271816A (zh) * 2012-05-11 2015-01-07 默沙东公司 表面锚定的轻链诱饵抗体展示系统
CN104349779A (zh) 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
TWI864338B (zh) * 2012-11-14 2024-12-01 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EA201591700A1 (ru) 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Гибридные белки апелина и их применение
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
PL3812453T3 (pl) 2013-10-11 2026-07-13 Regeneron Pharmaceuticals, Inc. Hodowla komórkowa zoptymalizowana metabolicznie
DK3076969T3 (da) 2013-12-06 2021-11-22 Novartis Ag Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
CN108472289A (zh) 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
WO2017132701A1 (en) * 2016-01-31 2017-08-03 Shuang Zhang Method for screening antibodies
EP4414484A3 (de) 2016-02-04 2025-01-15 Trianni, Inc. Erhöhte produktion von immunglobulinen
WO2017203046A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork Methods for increasing proliferation of mammalian cells
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
WO2018041740A1 (en) 2016-09-01 2018-03-08 Bayer Pharma Aktiengesellschaft Non-covalent display system using fimgt/dsf
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
EP3472198B1 (de) 2016-09-29 2020-03-04 H. Hoffnabb-La Roche Ag Verbessertes verfahren zur auswahl von polypeptidproduzierenden zellen
GB201703418D0 (en) 2017-03-03 2017-04-19 Ge Healthcare Bio Sciences Ab Method for cell line development
GB201704115D0 (en) * 2017-03-15 2017-04-26 Oxford Genetics Ltd Method of selecting for antibodies
JP7287940B2 (ja) * 2017-03-24 2023-06-06 ランケナウ・インスティテュート・フォー・メディカル・リサーチ ハイブリドーマによって分泌されるモノクローナル免疫グロブリンの誘導性細胞外膜捕捉のための方法及び組成物
US11833178B2 (en) 2017-08-25 2023-12-05 University College Cork—National University of Ireland, Cork Bifidobacterium longum for treating obesity and weight management
EP3713587B1 (de) 2017-11-24 2024-03-27 University College Cork-National University of Ireland, Cork Zusammensetzung mit einer kohorte von bakterien
EP3604507A1 (de) 2018-07-30 2020-02-05 University College Cork-National University of Ireland, Cork Omega-transaminase-enzym
US12492232B2 (en) 2018-09-17 2025-12-09 South Australian Health And Medical Research Institute Limited Methods for producing proteins
EP3945800A1 (de) * 2019-04-03 2022-02-09 Regeneron Pharmaceuticals, Inc. Verfahren und zusammensetzungen zum einfügen von antikörpercodierenden sequenzen in einen sicheren locus
EP3783012A1 (de) 2019-08-20 2021-02-24 Nuritas Limited Antimikrobielles peptid
JP2022545265A (ja) 2019-08-20 2022-10-26 ニューリタス リミテッド 筋萎縮を治療するためのペプチド
MX2022004872A (es) 2019-10-22 2022-05-13 Nuritas Ltd Tratamiento de enfermedad de higado graso no alcoholico.
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
AU2021244786A1 (en) 2020-03-25 2022-11-03 Risen (Suzhou) Pharma Tech Co., Ltd. Stable heavy isotopes in amide functional groups and uses thereof
US20240310375A1 (en) * 2021-03-10 2024-09-19 Sony Group Corporation Bioparticle analysis method and reagent kit for bioparticle analysis
EP4070670A1 (de) 2021-04-08 2022-10-12 University College Cork-National University of Ireland Cork Lacticaseibacillus paracasei em025-11 und verwendungen davon
CN117642176A (zh) 2021-04-14 2024-03-01 爱尔兰国立科克大学 Psg1用于治疗骨关节炎
WO2022219008A1 (en) 2021-04-14 2022-10-20 University College Cork - National University Of Ireland, Cork Treatment of cerebrovascular events and neurological disorders
EP4413359A1 (de) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Ph-messgerät-kalibrierung und -korrektur
EP4413364A2 (de) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Systeme und verfahren zur ph-modellierung und -steuerung
EP4486778A1 (de) 2022-03-02 2025-01-08 Regeneron Pharmaceuticals, Inc. Herstellungsverfahren für antikörper mit hohem titer
JP2025534040A (ja) 2022-10-14 2025-10-09 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 腱傷害の治療における使用のための胎盤発現タンパク質
WO2025133254A2 (en) 2023-12-20 2025-06-26 Nuritas Limited Angiotensin-converting enzyme (ace) inhibiting peptides.
AU2024402215A1 (en) 2023-12-20 2026-06-25 Nuritas Limited Sleep promoting peptides and the use thereof
CN118006552A (zh) * 2024-04-09 2024-05-10 暨南大学 一种抗原特异性浆细胞的筛选方法及其应用
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679949B2 (en) * 1992-10-21 1997-07-17 Stefan Miltenyi Direct selection of cells by secretion product
US6287784B1 (en) * 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
CA2330678C (en) * 1998-05-11 2009-04-07 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific t cells
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
DE19900635A1 (de) * 1999-01-11 2000-07-13 Deutsches Krebsforsch Selektion von monoklonalen Antikörpern
ATE325865T1 (de) * 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen

Also Published As

Publication number Publication date
DE60211329D1 (de) 2006-06-14
WO2002057423A3 (en) 2003-12-18
EP1392859A4 (de) 2004-11-24
US20020168702A1 (en) 2002-11-14
DE60211329T2 (de) 2007-05-24
US6919183B2 (en) 2005-07-19
JP2004520037A (ja) 2004-07-08
IL156910A0 (en) 2004-02-08
EP1392859B1 (de) 2006-05-10
EP1392859A2 (de) 2004-03-03
AU2002245272B2 (en) 2006-06-29
CA2434802A1 (en) 2002-07-25
US7435553B2 (en) 2008-10-14
JP4323167B2 (ja) 2009-09-02
US20060234311A1 (en) 2006-10-19
US20050186623A1 (en) 2005-08-25
WO2002057423A2 (en) 2002-07-25
CA2434802C (en) 2013-05-28
IL156910A (en) 2009-08-03
HK1059290A1 (en) 2004-06-25

Similar Documents

Publication Publication Date Title
DE60211329D1 (de) Isolierung von sezernierte proteine exprimierenden zellen
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
WO2003068947A8 (en) Assay electrodes having immobilized lipid/protein layers and methods of making and using the same
Budayeva et al. A mass spectrometry view of stable and transient protein interactions
ATE528648T1 (de) Verfahren zum nachweis antikörper-herstellender zellen
WO2003012068A3 (en) Novel fusion proteins and assays for molecular binding
WO2000054046A3 (en) Universal protein array system
WO2003033731A3 (en) Methods for detecting ovarian cancer
WO2002086450A3 (en) Compositions and methods for the identification of protein interactions in vertebrate cells
DE50107766D1 (de) Zweifarbiges fluorimetrisches proteaseassay
WO2003020005A3 (en) Lp mammalian proteins; related reagents
WO2003016904A3 (en) Peptide sequence tags and method of using same
WO2003012089A3 (en) Crystal structure of beta-site app cleaving enzyme (bace) and use thereof
DE60115103D1 (de) Biomolekülanalyse auf array-basis
WO2002064747A3 (en) Fusion proteins based upon somatostatin receptors
WO2005001099A8 (en) Protein expression system
Liu et al. Screening microorganisms with robust and stable protein expression and secretion capacity
HUP0101987A2 (hu) Antibiotikus hatású proteinek és peptidek indukciója LAIT/sCD14-proteinnel
WO2003072041A3 (en) Assays to monitor amyloid precursor protein processing
ATE348190T1 (de) Verfahren zum nachweis von protein- proteininteraktionen in membranen
WO2005047305A3 (en) Cellular membrane protein assay
WO2002074906A3 (en) Lp mammalian proteins; related reagents
WO2002050104A3 (en) Methods and cells for detecting modulators of rgs proteins
WO2006004936A3 (en) Analysis of intracellular modifications
WO1999047673A3 (en) Isolated mammalian membrane protein genes and related reagents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1392859

Country of ref document: EP